Management of Locally Advanced Renal Cell Carcinoma

Initial Evaluation and Staging

The European Society for Medical Oncology (ESMO) recommends obtaining high-quality multiphase cross-sectional imaging to fully characterize the extent of local invasion, venous involvement, and nodal disease for patients with cT3aN1M0 left renal cell carcinoma 3, 4
The American Urological Association (AUA) suggests performing comprehensive laboratory assessment, including complete metabolic panel with calculated GFR, complete blood count, and urinalysis to assess baseline renal function and overall health status for patients with renal cell carcinoma 3, 4
Complete metastatic evaluation with chest imaging is recommended to rule out distant metastases in patients with cT3aN1M0 left renal cell carcinoma 3, 4
Assigning CKD stage based on GFR and degree of proteinuria is crucial, as this will influence perioperative management and long-term prognosis for patients with renal cell carcinoma 3, 4

The ESMO guidelines state that open radical nephrectomy remains the standard of care for locally advanced T3a disease, though laparoscopic approaches may be considered in highly selected cases with adequate surgical expertise 1, 2
Radical nephrectomy with regional lymph node dissection is the recommended initial surgical approach for patients with cT3aN1M0 left renal cell carcinoma, as this locally advanced disease with nodal involvement requires complete oncologic resection 1, 2
Performing regional lymph node dissection is recommended given the clinical N1 status, as this provides both staging information and potential therapeutic benefit for patients with cT3aN1M0 left renal cell carcinoma 1, 2
Systematic adrenalectomy should not be performed unless imaging demonstrates direct adrenal involvement for patients with renal cell carcinoma 1, 2

Adjuvant VEGFR-targeted therapy remains controversial, as while the S-TRAC trial showed improved disease-free survival with adjuvant sunitinib, there was no overall survival benefit for patients with renal cell carcinoma 1, 2
The European Medicines Agency has not approved adjuvant therapy due to imbalance between risk and clinical benefit for patients with renal cell carcinoma 1, 2
Pooled analysis of major adjuvant trials showed no statistically significant DFS or OS improvement, though high-risk disease may derive more benefit from adjuvant therapy for patients with renal cell carcinoma 1, 2

Medical oncology should be included in preoperative planning to discuss potential adjuvant therapy options for patients with locally advanced renal cell carcinoma 3, 4
Nephrology referral should be considered if baseline GFR <45 mL/min/1.73m², confirmed proteinuria, or expected post-nephrectomy GFR <30 for patients with renal cell carcinoma 3, 4
An experienced surgical team is essential given the technical challenges of T3a disease with potential venous involvement for patients with renal cell carcinoma 1, 2